文献速递白血病造血干细胞移植与细胞治疗

CD155/PVR决定Delta One T细胞对急性髓系白血病的靶向作用

CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells.
PubMed 文献 · Blood · 2024-01-01

研究探讨了Delta One T(DOT)细胞识别急性髓系白血病(AML)细胞的分子机制。筛选多种AML细胞系发现DNAM-1配体CD155/PVR和CD112/nectin-2及NKp30配体B7-H6显著上调,CRISPR敲除证实PVR和B7-H6对DOT细胞靶向AML细胞有非冗余和协同贡献,且原代AML样本中PVR而非B7-H6表达可预测DOT细胞对其的清除。

要点

  • DOT细胞对AML细胞的靶向依赖PVR和B7-H6的非冗余协同作用,nectin-2不参与。
  • PVR和B7-H6对AML细胞与DOT细胞间形成稳固免疫突触至关重要。
  • 原代AML样本中PVR而非B7-H6的表达预测DOT细胞对其的清除。

核心结论

  • PVR和B7-H6对DOT细胞靶向AML细胞有关键非冗余协同贡献,原代AML中PVR表达预测DOT细胞清除,提示评估PVR表达水平可能与DOT细胞临床试验高度相关。

研究设计与样本

  • 体外研究:筛选多种AML细胞系,采用CRISPR介导的基因敲除,并检测原代AML样本。

主要发现

  • 多种AML细胞系中DNAM-1配体CD155/PVR、CD112/nectin-2及NKp30配体B7-H6强烈上调,而NKG2D配体与之形成对比。
  • CRISPR敲除显示PVR和B7-H6而非nectin-2对DOT细胞靶向AML细胞有非冗余和协同贡献。
  • PVR和B7-H6对AML细胞与DOT细胞间形成稳固免疫突触至关重要。
  • 原代AML样本中PVR而非B7-H6表达预测DOT细胞对其的清除。

临床怎么用

  • 作者认为评估PVR表达水平可能与基于DOT细胞的临床试验高度相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed or refractory acute myeloid leukemia (AML) remains a major therapeutic challenge. We have recently developed a Vδ1+ γδ T cell-based product for adoptive immunotherapy, named Delta One T (DOT) cells, and demonstrated their cytolytic capacity to eliminate AML cell lines and primary blasts in vitro and in vivo. However, the molecular mechanisms responsible for the broad DOT-cell recognition of AML cells remain poorly understood. Here, we dissected the role of natural killer (NK) cell receptor ligands in AML cell recognition by DOT cells. Screening of multiple AML cell lines highlighted a strong upregulation of the DNAM-1 ligands, CD155/pulmonary vascular resistance (PVR), CD112/nectin-2, as well as the NKp30 ligand, B7-H6, in contrast with NKG2D ligands. CRISPR-mediated ablation revealed key nonredundant and synergistic contributions of PVR and B7-H6 but not nectin-2 to DOT-cell targeting of AML cells. We further demonstrate that PVR and B7-H6 are critical for the formation of robust immunological synapses between AML and DOT cells. Importantly, PVR but not B7-H6 expression in primary AML samples predicted their elimination by DOT cells. These data provide new mechanistic insight into tumor targeting by DOT cells and suggest that assessing PVR expression levels may be highly relevant to DOT cell-based clinical trials.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mensurado S, Condeço C, Sánchez-Martínez D, et al. CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells. Blood. 2024. PMID: 38437507. doi:10.1182/blood.2023022992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。